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Aims A sequence variant, rs7025486[A], in DAB2IP on chromosome 9q33 has recently been associated with coronary
heart disease (CHD). We sought to replicate this ﬁnding and to investigate associations with a panel of inﬂammatory
and haemostatic biomarkers. We also sought to examine whether this variant, in combination with a chromosome
9p21 CHD variant (rs10757278) and the Framingham risk score (FRS), could improve the prediction of events com-
pared with the FRS alone.
Methods
and results
rs7025486 was genotyped in 1386 CHD cases and 3532 controls and was associated with CHD [odds ratio (OR) of
1.16, 95% conﬁdence interval (CI) 1.05–1.29, P ¼ 0.003]. Meta-analysis, using data from the original report and from
genome-wide association studies in both the Wellcome Trust Case Control Consortium and the Cardiovascular
Health Study, comprising 9968 cases and 20 048 controls, conﬁrmed the association (OR of 1.10, 95% CI 1.06–
1.14, P ¼ 3.2 × 10
26). There was no association with a panel of CHD biomarkers, including any lipid, inﬂammation,
or coagulation trait, nor with telomere length. Addition to the FRS of this variant plus rs10757278 on chromosome
9p21 improved the area under the receiver-operating characteristic curve (AROC) from 0.61 to 0.64 (P ¼ 0.03) as well
as improving the reclassiﬁcation (net reclassiﬁcation index ¼ 11.1%, P ¼ 0.007).
Conclusion This study replicates a previous association of a variant in DAB2IP with CHD. Addition of multiple variants improves
the performance of predictive models based upon classical cardiovascular risk factors.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
A recent genome-wide association study (GWAS) found a
sequence variant in DAB2IP (rs7025486[A]) to be strongly associ-
ated with the presence of abdominal aortic aneurysm (AAA) with a
per-allele odds ratio (OR) of 1.21 (P ¼ 4.6 × 10
210).
1 The authors
also found an association with early-onset myocardial infarction
(MI) (OR 1.18, P ¼ 3.1 × 10
25), MI at all ages (OR ¼ 1.08, P ¼
0.0012), peripheral arterial disease (PAD) (OR ¼ 1.14, P ¼ 3.9 ×
10
25), venous thrombo-embolism (VTE, OR 1.12, P ¼ 0.0079),
and pulmonary embolism (OR ¼ 1.20, P ¼ 0.00030) but not intra-
cranial aneurysm or ischaemic stroke. This variant did not appear
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doi:10.1093/eurheartj/ehr075to act through classical intermediate phenotypes such as smoking,
lipids, obesity, type 2 diabetes (T2DM), and hypertension.
DAB2IP, located on chromosome 9q33, is a GTPase-activating
protein thought to play an important role in prostate cancer
metastasis.
2 A single-nucleotide polymorphism (SNP) in this gene
has been associated with aggressive prostate cancer,
3 whereas in
vitro functional studies have demonstrated that loss of the
protein leads to enhanced cell proliferation and reduced apoptosis,
via the Pi3-Akt pathway.
4 It is possible therefore, that this SNP
exerts its effect by regulating cell senescence and proliferation. In
2007, three groups reported that another locus on the short
arm of chromosome 9 at p21.3, tagged by the SNP rs10757278,
was strongly associated with coronary heart disease (CHD).
5–8
This SNP was also subsequently found to be associated with the
risk of AAA and PAD but does not appear to act through classical
intermediate phenotypes.
5–7,9–11 There is mounting evidence to
suggest that this SNP affects expression of the large non-coding
RNA ANRIL, which in turn may affect expression of nearby genes
such as the CDKN2A/B cluster which also play a role in cellular pro-
liferation and senescence.
12–14
We aimed to conﬁrm the association of rs7025486[A] with
CHD. In addition, associations with circulating biomarkers of car-
diovascular disease (CVD), including lipids, inﬂammatory
markers, and haemostatic markers, were investigated. Since
shorter leucocyte telomere length (LTL) has been consistently
shown to be associated with increased risk of CHD
15,16 in both
population-based case–control studies and patients with familial
hypercholesterolaemia (FH), a monogenic form of premature
CHD, we examined the relationship between this SNP and telo-
mere length. Finally, whether or not this variant, in combination
with the 9p21 locus and the Framingham risk score (FRS), could
improve the prediction of CHD over and above the FRS alone
in the Northwick Park Heart Study II (NPHS-II) prospective
study of UK men was investigated.
Methods
Study groups
Table 1 shows the baseline characteristics of each of the studies used.
Ethics approval was granted for all studies. Detailed descriptions of
each study are provided elsewhere. NPHS-II is a prospective study
of healthy middle-aged men (50–64 years) recruited from nine UK
general practices.
17 In the 2742 Caucasian men with genotype data,
by December 2009, there had been 272 CHD events comprising
175 acute CHD events (42 fatal), 74 coronary artery revascularization
procedures, and 23 silent MI. The HIFMECH study
18 compares male
survivors of a ﬁrst MI aged ,60 years (excluding patients with FH
and insulin-dependent diabetes mellitus) and population-based individ-
uals of the same age and region recruited from four centres in Europe:
Stockholm (Sweden) and London (England) for the North and Mar-
seille (France) and San Giovanni Rotondo (Italy) representing the
south. In all, a total of 598 post-infarction patients and 653 controls
were included in the study. The Simon Broome Study recruited 409
patients with deﬁnite FH (all with a total cholesterol concentration
of .7.5 mmol/L) with 127 deﬁnite CHD events as deﬁned in Neil
et al.
19 The UDACS
20 consists of 1014 consecutive subjects recruited
from the diabetes clinic at University College London Hospitals NHS
Trust (UCLH) 2001–02 (629 men; 600 Caucasians with T2DM). All
patients had diabetes according to the WHO criteria and analysis
was restricted to the Caucasian subjects with T2DM to remove poss-
ible heterogeneity within the sample. Coronary heart disease was
deﬁned in Wootton et al.
20 The coronary artery bypass graft
(CABG) patients were drawn from the coronary artery surgery inﬂam-
mation study and are described elsewhere.
21 Brieﬂy, all patients under-
going elective ﬁrst-time CABG at the Middlesex Hospital, London, UK,
between October 1999 and September 2000 were invited to partici-
pate. Subjects undergoing additional surgical procedures (such as valv-
ular surgery or aneurysmectomy), subjects with evidence of a
pre-existing inﬂammatory state or unstable coronary artery disease,
and subjects who suffered potentially confounding infective post-
operative complications or circulatory failure requiring inotropic
support were excluded. The CABG group includes 439 people (20%
women) having different ethnic origin (83% Caucasians, 8% Asians,
2% Afro-Caribbean, 2% of other ethnicity, and 5% of unknown
origin). Non-Caucasian subjects were excluded from the genetic
analysis.
In silico analysis
The Cardiovascular Health Study is a longitudinal study of 3291 men
and women, primarily of self-described European ancestry, who
were free of clinical CVD at baseline, consented to the use of their
DNA for cardiovascular research, and were successfully genotyped
on the Illumina 370 CNV platform. There were 532 incident CHD
events during follow-up. Data from the Cardiovascular Health Study
GWAS of MI were accessed through a publicly available database
(http://www.ncbi.nlm.nih.gov/gap). Data from the WTCCC of coronary
disease
22 were accessed, which included genotype data on 1988 CHD
cases and 3004 controls from the National Blood Service and the 1958
Birth Cohort.
Genotyping
rs7025486 and rs10757274 were genotyped using TaqMan technology
[Applied Biosciences (ABI), Warrington, UK]. Reactions were per-
formed on 384-well microplates and analysed using ABI TaqMan
7900HT software (Applied Biosciences).
Measurement of telomere length
Leucocyte DNA was extracted by the salting-out method.
15 Leucocyte
telomere length was measured using a quantitative polymerase chain
reaction (PCR)-based method,
23 as adapted in our laboratory. The
relative telomere length was calculated as the ratio of telomere
repeats to single-copy gene (SCG) copies (T/S ratio). For each
sample, the quantity of telomere repeats and that of SCG copies
were determined in comparison to a reference sample in a telomere
and an SCG quantitative PCR, respectively. All PCRs were performed
in duplicate on the Rotor-Gene 6000 (Corbett Research Ltd, Cam-
bridge, UK), and the raw data were analysed using the comparative
quantiﬁcation analysis (Rotor-Gene 6000 software, Corbett Research
Ltd). The speciﬁcity of all ampliﬁcations was determined by melting
curve analysis. Using the linear regression line between measures
obtained by both the PCR-based method and the conventional term-
inal restriction fragment analysis for the same set of 32 samples, as pre-
viously described, the corresponding telomere length in base pairs (bp)
was calculated from the T/S ratio measured in each subject.
15
Statistical analysis
Allelefrequenciesbetweengroupswerecomparedusingx
2test,andwe
testedfordeparturefromtheHardy–Weinbergequilibriumincontrols.
Mean values for continuous variables were compared between those
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Table 1 Baseline characteristics of studies
UDACS NPHS-II Simon Broome HIFMECH CABG
CHD2,
n 5 358
CHD1,
n 5 135
P-value CHD2,
n 5 2406
CHD1,
n 5 274
P-value CHD2,
n 5 214
CHD1,
n 5 127
P-value CHD2,
n 5 554
CHD1,
n 5 518
P-value CHD,
n 5 332
Age (years) 66.2 (10.9) 69.5 (9.9) 0.003 56.0 (3.4) 56.6 (3.5) 0.01 44.6 (13.8) 56.5 (10.4) ,0.001 51.5 (5.4) 51.9 (5.4) — 64.9 (9.2)
% male 56.4 (202) 69.6 (94) 0.008 100 (2406) 100 (274) — 43.0 (92) 66.9 (85) ,0.001 100 (554) 100 (518) — 81.9 (272)
SBP (mmHg) 142.0 (18.5) 137.9 (20.5) 0.03 136.8 (18.6) 141.4 (19.4) 0.0002 124.1 (16.3) 130.8 (19.9) 0.001 128.1 (14.5) 127.7 (16.8) 0.71
DBP (mmHg) 79.5 (10.9) 77.1 (10.5) 0.03 84.4 (11.2) 86.8 (11.5) 0.0008 76.6 (9.9) 78.5 (13.1) 0.14 84.1 (8.5) 81.6 (10.2) ,0.001
BMI (kg/m
2) 29.2 (5.3) 29.5 (5.3) 0.54 26.2 (3.4) 26.6 (3.3) 0.05 23.7 (4.0) 25.2 (3.5) 0.003 26.1 (3.2) 27.0 (3.3) ,0.001 28.5 (4.5)
%e v e r
smokers
50.7 (173) 59.9 (79) 0.08 67.3 (1618) 77.7 (213) ,0.001 38.5 (82) 65.4 (83) ,0.001 61.9 (343) 82.1 (425) ,0.001 78.0 (259)
Cholesterol
(mmol/L)
5.19 (1.06) 4.68 (1.11) ,0.001 5.71 (1.01) 6.07 (1.02) ,0.001 6.85 (1.28) 6.28 (1.32) ,0.001 5.53 (0.98) 5.39 (1.18) 0.04 4.79 (1.10)
Triglyceride
(mmol/L)
1.94 (1.10) 1.96 (1.08) 0.85 1.77 (0.93) 2.05 (1.07) ,0.001 1.24 (0.54) 1.44 (0.67) 0.003 1.44 (0.61) 1.87 (0.76) ,0.001
CRP (g/L) 1.70 (1.41) 1.86 (1.59) 0.27 2.46 (2.43) 3.26 (3.33) ,0.001 1.19 (1.39) 1.48 (1.72) 0.11 1.24 (1.42) 2.23 (2.53) ,0.001 2.25 (2.75)
Fibrinogen
(g/L)
— — — 2.70 (0.52) 2.80 (0.49) 0.002 2.77 (0.82) 3.07 (1.00) 0.003 3.41 (0.69) 3.71 (0.92) ,0.001 3.63 (0.77)
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3with and without CHD using unpaired t-tests. Where necessary, vari-
ables were log-transformed before analysis and results are presented
asgeometricmeanswithapproximatestandarddeviationsforthesevari-
ables. Categorical variables were compared using x
2 tests. Genetic
associationswere testedusingregressionmodels using an additive (per-
allele) model. Hazard ratios (HRs) were calculated in the prospective
study (NPHS-II), using Cox’s regression models with corresponding
95% conﬁdence intervals (CIs). Odds ratios and their corresponding
95% CIs were calculated from case–control and cross-sectional
studies using logistic regression models. Gene–disease associations
were adjusted for age as a continuous outcome. In NPHS-II, analyses
are stratiﬁed by general practice. For the conventional model, a score
wasderivedbased on age, triglycerides, cholesterol, smoking, and systo-
lic blood pressure. We then ﬁtted a model including both conventional
factors and rs7025486 and rs10757274 genotypes and obtained a
second score by weighting according to the b coefﬁcients from the
model. The area under the receiver-operating characteristic (ROC)
curve was calculated for both scores and the difference between the
conventional model and that incorporating genotypes was tested. We
assessed the effect of adding the genetic variables on the ability of the
score to assign participants to the correct risk category using the net
reclassiﬁcation index (NRI).
24
For meta-analysis of CHD outcomes, study-speciﬁc ORs and stan-
dard errors were obtained and pooled generating a summary estimate
and its 95% CI. There was no evidence of between-study heterogen-
eity (I
2 ¼ 0%); therefore, a ﬁxed-effects model was used. An additive
model was used to conﬁrm the association for additive effects found
by Gretarsdottir et al.
1 All analyses were carried out using Stata
version 10 (Statcorp, TX, USA).
Results
The characteristics of the study groups are presented in Table 1,
which show the expected differences in classical risk factors in
cases compared with controls and in baseline characteristics in
those who subsequently went on to develop CHD in the prospec-
tive NPHS-II study. In the UDACS study, many risk factors are
higher in the CHD-negative group, which is indicative of higher
proportion cases being treated with statins and blood pressure-
lowering medication. For both SNPs, the genotype distributions
were as expected from the Hardy–Weinberg principles with the
risk-allele frequency for the DAB2IP SNP rs7025486 ranging from
0.222 to 0.294 and for the Chr9p SNP rs10757274 ranging from
0.482 to 0.608.
Association of rs7025486 with coronary
heart disease
Ineachofthestudygroups,therareallelewasassociatedwith1.08–
1.34 higher risk of CHD, although only one of these (CABG vs.
healthy controls in NPHS-II) was nominally statistically signiﬁcant
using a P-value threshold of 0.05 (OR 1.2, 95% CI 1.03–1.46, P ¼
0.021). Pooled analysis of the results from each of the studies
(Figure 1A) demonstrated that there was a consistent association
between rs7025486 and CHD (OR 1.16, 95% CI 1.05–1.29, P ¼
0.003). Meta-analysis of data from the original report,
1 the newly
genotyped studies, and the WTCCC and CVHS GWAS data also
demonstrated a consistent association (OR 1.1, 95% CI 1.06–1.14,
P ¼ 3.2 × 10
26), forest plot shown in Figure 1B.
Association of rs7025486 with
intermediate traits
There was no signiﬁcant association between this SNP and any of
the cardiovascular biomarkers examined including lipid proﬁles and
inﬂammatory markers (C-reactive protein and interleukin-6) or
phenotypes such as stroke and diabetes. In addition, we found
no association with a panel of haemostatic markers including ﬁbri-
nogen, plasminogen activator inhibitor-1 (PAI-1), and a number of
clotting factors, nor with the telomere length (see Supplementary
material online, Tables 2a–d, Figure 4).
Conventional risk factors and coronary
heart disease events
The baseline characteristics of the NPHS-II, stratiﬁed by sub-
sequent CHD event, are presented in Table 1. The men who
went on to develop CHD during follow-up (n ¼ 274) were
older, had higher plasma cholesterol, triglycerides, and blood
pressure, and had lower HDL-cholesterol, and the prevalence of
smoking was higher than in those who remained CHD free (n ¼
2406). On the basis of the measured variables included in the Fra-
mingham algorithm, the AROC given by this set of classical risk
factors (CRFs) was 0.61 (95% CI 0.572–0.651) (Figure 2). We
created a simple additive ‘gene score’ (GS) based upon carriage
of rs7025486 and rs10757278, combined with CRFs, to assess
whether or not it would improve risk prediction and stratiﬁcation
compared with CRFs alone. There was no statistical evidence of
interaction between these SNPs (see Supplementary material
online, Table 3), and the AROC for these two SNPs alone was
0.577 (95% CI 0.540–0.614). The AROC for the model that
included both CRFs and genotypes was 0.64 (95% CI 0.598–
0.675; Figure 2), which was a small but statistically signiﬁcant
improvement when compared with the value achieved by CRFs
alone (P ¼ 0.03). The numbers of patients reclassiﬁed using the
model that included CRFs and the two SNPs are shown in
Table 2. The NRI was 11.1% which was statistically signiﬁcant (P
¼ 0.007). A Kaplan–Meier plot of freedom from CHD with
increasing numbers of risk alleles carried is shown in Figure 3,
demonstrating the added effect on risk of carriage of more than
one risk allele.
Discussion
This study is the ﬁrst to replicate the association between
rs7025486 and the risk of CHD following the initial publication.
1
Figure 1A and B demonstrate that the effect size in different
groups of subjects is extremely consistent, even with differing
underlying aetiologies such as T2DM or FH, and in case–control
and prospective studies, including previous published GWAS.
Although only 1 of the 15 studies included in the meta-analysis
passed a conventional P-value threshold of 0.05 for single
SNP-disease association, this is not unexpected given the minor-
allele frequency (MAF) and modest effect size. The fact that in
all 15 studies the minor allele increased the risk of CHD with a
comparable effect suggests that this association is unlikely to be
a false-positive, reﬂected by the combined P-value. Indeed, it is
becoming clear that the initial wave of GWAS has detected only
S.C. Harrison et al. 884SNPs with the largest effect and favourable MAFs (the so-called
‘low-hanging fruit’). Even meta-analysis of GWAS, involving many
thousands of subjects, may be underpowered to detect all SNPs
with modest effects sizes. Therefore, single SNP studies guided
by the ﬁndings of GWAS are likely to be an important method
to decipher which of the many associations that fail to reach
genome-wide levels of signiﬁcance are actually true positives.
Furthermore, although the fact that the effect sizes of newly dis-
covered variants such as this are small, this does not preclude
important biological insights being made. The fact that this
variant has a similar effect in differing CHD aetiologies, and that
there is no association with established biomarkers, implies that
this variant is acting through pathways independent of those
classically associated with CHD such as lipid metabolism. DAB2IP
is involved in regulating cell survival and senescence, and the
association seen here adds to emerging evidence (seen with the
strong association between the 9p21 locus and CHD) that
genetic variants in genes that regulate the cell cycle may be an
important mediators of CVD. The additive effect on risk of
CHD seen with these two SNPs implies that the accumulation of
variants of modest effect in this pathway is an important indepen-
dent mediator of CHD development (as suggested by the common
variant hypothesis) and highlights potential targets for the develop-
ment of novel therapeutic options.
The original report found an association with VTE and pulmon-
ary embolism,
1 so we hypothesized that this variant may act
Figure 1 (A) Meta-analysis studies genotyped in this paper for association between rs7025486 and coronary heart disease. Combined odds
ratio (95% conﬁdence interval) is 1.16 (1.05–1.29); P ¼ 0.003. Fixed-effects additive genotype model. (B) Meta-analysis of association between
rs7025486 and coronary heart disease, including newly genotyped, previously published data and genome-wide association study data from the
WTCCC and CVHS. Odds ratio 1.10 (95% conﬁdence interval 1.06–1.14, P ¼ 3.2 × 10
26). Fixed-effects additive genotype model.
Association of a variant in DAB2IP with CHD 885through pathways that promote thrombosis but found no signiﬁ-
cant associations with a panel of haemostatic markers including
ﬁbrinogen, PAI-1, and numerous clotting factors. Shorter telo-
meres are associated with premature CHD; however, no consist-
ent association between this SNP and mean LTL was found in
2012 subjects examined.
It is unlikely that a single SNP of modest effect will improve the
prediction of CVD when compared with a risk score based upon
multiple CRFs.
25 It is much more likely, however, that variants
found to be associated with CHD, which do not act through inter-
mediate phenotypes such as lipid traits, which are already included
in such risk scores, will be of use when combined with CRFs. It has
been reported that addition of the single chromosome 9 SNP
(rs10757278) to the FRS did not improve prediction (as measured
by the AROC).
25 In this study, we show that addition of two SNPs to
the FRS improved the AROC by 0.03 which was statistically signiﬁ-
cant (P ¼ 0.001). Although the two SNPs show no statistical evi-
dence of interaction, the study has limited power to detect such
interactive effects, and possibly because of small numbers, risk
was not highest in men carrying all four risk alleles. Such effects
will need to be conﬁrmed in larger studies. Because of the high fre-
quency of both of the risk alleles, 38% of these UK men carry one
risk allele, 34% carry two, and 14% carry three or four risk alleles,
with those carrying two or more having an HR of over 1.7.
The AROC is a commonly used statistic to describe the discrimi-
native ability of a diagnostic test, but the number itself provides
........................................................................................................................
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Table 2 Reclassiﬁcation based on the Framingham risk score 1 gene score
Predicted CHD risk
Framingham 1 GS
Predicted CHD risk
No. of individuals Reclassiﬁed Net correctly
reclassiﬁed
Framingham
<5% 5–10% 10–20% >20% Increased risk Decreased risk
Individuals without CHD during follow-up (n ¼ 2009)
0t o,5% 89 13 0 0 297 371 3.7%
5–10% 134 769 240 0
10–20% 0 227 467 44
≥20% 0 0 10 16
Individuals with CHD during follow-up (n ¼ 216)
0t o,5% 4 0 0 0 45 29
5–10% 5 65 27 0 7.4%
10–20% 0 21 67 18
≥20% 0 0 3 6
Net reclassiﬁcation improvement (95% CI) 11.1% (2.9–19.4)
The percentage correctly reclassiﬁed by adding gene score to the Framingham variables is 11.1% (P ¼ 0.007). Green signiﬁes correctly reclassiﬁed, yellow no reclassiﬁcation and
red incorrectly reclassiﬁed.
Figure 3 The Kaplan–Meier plot for coronary heart disease
and the number of risk alleles carried. Compared with the refer-
ence group of those with no risk alleles, the age- and
practice-adjusted hazard ratio for those with only one
allele ¼ 1.19 (0.78–1.84), P ¼ 0.42, for any two alleles ¼ 1.79
(1.16–2.75), P ¼ 0.008, and for three and four alleles ¼ 1.75
(1.07–2.85) P ¼ 0.025. Overall P ¼ 0.005.
Figure 2 Receiver-operating characteristic curve for different
prediction models in NPHS-II men. The area under the receiver-
operating characteristic curve increases from 0.61 to 0.64 when
the gene score is added to the Framingham variables (P ¼ 0.03).
S.C. Harrison et al. 886little clinically useful information. In the UK, the FRS is used to clas-
sify the population into risk groups that guide clinicians when plan-
ning treatment. In the UK, treatment with a statin is recommended
in individuals with a 10-year risk .20%.
26 In the NPHS-II at recruit-
ment, adopting this policy would result in just 35 (1.6%) of men
being offered treatment, in part because men with prevalent
CHD or being treated with preventative medications were
excluded.
17 We found that addition of the two-SNP gene score
to the FRS improved risk stratiﬁcation as measured by the NRI
of 11.1% (P ¼ 0.007, 95% CI 2.9–19.4). If a policy was adapted
whereby people with an FRS . 20% or an FRS + GS . 20% in
the NPHS-II cohort were offered treatment, then the number of
men who would qualify increases three-fold in the group who
went on to develop CHD. It has been observed that the FRS
tends to over-predict CVD in high-risk groups but under-predict
CVD in low-risk groups.
27,28 Compared with the general popu-
lation, the participants in NPHS-II are a healthy cohort which is
one reason why the FRS performs poorly as measured by the
AROC. We have shown that in this group of patients, the addition
of genotypes to the prediction model improved performance as
measured by the AROC and the more clinically relevant NRI.
Further research is required to assess whether or not these
results are applicable on a population level.
Conclusion
This study has conﬁrmed the effects of a common variant in
DAB2IP (rs7025486) on the development of CHD. Prediction
models which include CRFs and genotypes, which act through
pathways independent of the CRFs, are likely to improve their per-
formance. Even the small increment in AROC seen in this study has
potential clinical utility when thresholds used for treatment in the
UK are considered. Understanding the mechanism by which this
variant exerts its effect should be the focus of ongoing research.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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